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We have identiﬁed a patient affected by a relatively severe form of central core disease (CCD), carrying a
heterozygous deletion (amino acids 4863–4869) in the pore-forming region of the sarcoplasmic reticulum
calcium release channel. The functional effect of this deletion was investigated (i) in lymphoblastoid cells from
the affected patient and her mother, who was also found to harbour the mutation and (ii) in HEK293 cells
expressing recombinant mutant channels. Lymphoblastoid cells carrying the RYR1 deletion exhibit an
‘unprompted’ calcium release from intracellular stores, resulting in signiﬁcantly smaller thapsigargin-
sensitive intracellular Ca2þ stores, compared with lymphoblastoid cells from control individuals. Blocking the
RYR1 with dantrolene restored the intracellular calcium stores to levels similar to those found in control cells.
Single channel and [3H]ryanodine binding measurements of heterologously expressed mutant channels
revealed a reduced ion conductance and loss of ryanodine binding and regulation by Ca2þ. Heterologous
expression of recombinant RYR1 peptides and analysis of their membrane topology demonstrate that the
deleted amino acids are localized in the lumenal loop connecting membrane-spanning segments M8 and M10.
We provide evidence that a deletion in the lumenal loop of RYR1alters channel function and causes CCD.
INTRODUCTION
The ryanodine receptors (RYR) are a family of intracellular
calcium release channels found in a variety of tissues and cell
types. At least three different isoforms have been identified and
characterized at the molecular level (for review see 1). Type 1 RYR
is predominantly expressed in skeletal muscle and is encoded by a
gene of 106 exons that maps to human chromosome 19q13.1 (2).
The human RYR1 gene encodes 5037 amino acids giving rise to
one of the largest known proteins (3,4). The functional calcium
release channel assembles as a macromolecular complex of more
than 2.5 MDa and is composed of four RYR1 subunits of 565 kDa
each and a number of accessory proteins which are thought to
regulate and stabilize the calcium channel (5–7).
To date more than 40 missense mutations have been
identified in the RYR1 gene and are associated with central
core disease (CCD; OMIM no.117000) and/or the malignant
hyperthermia susceptible phenotype (MHS; OMIM no.145600)
(for recent reviews see 8–10). CCD is a rare congenital
myopathy of autosomal dominant inheritance (11,12). Affected
individuals present with infantile hypotonia (floppy infant
syndrome) and a delay in achieving motor milestones. Later
in life, the predominant symptom is a generalized muscle
weakness affecting the proximal muscle groups more than
the distal ones. The clinical severity is highly variable, but the
course is usually slow or non-progressive. Additional clinical
features may include congenital hip dislocation, kyphoscoliosis,
foot deformities and joint contractures. The diagnosis is
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difficult on the basis of clinical findings alone and a
histological examination of muscle tissue is essential.
Typically, type I fibres predominate and, on cross sections,
contain single, well-demarcated and centrally located cores,
which do not stain with oxidative and phosphorylase
histochemical stains. In longitudinal sections the amorphous-
looking areas run along the length of the fibres (13–15).
Malignant hyperthermia (MH) is an autosomal dominant
pharmacogenetic disease triggered by volatile anaesthetics and
depolarizing muscle relaxants in genetically predisposed indi-
viduals (16–18). Symptoms include skeletal muscle rigidity,
tachycardia, hyperthermia, acidosis, cardiac arrhythmias and
rhabdomyolysis (8,19,20). In some individuals MH reactions
appear to be triggered by physical exercise and emotional
stress, leading some authors to suggest that MH, heat stroke and
exercise-induced rhabdomyolysis have a common denominator
(18,21,22).
The mutated codons giving rise to CCD and MH are clustered
in three regions of the RYR1 gene: region 1, extending from
Met1 to Arg614; region 2, extending between Arg2162 and
Arg2458; and region 3, which spans the highly conserved
C-terminal domain encompassing amino acid sequences which
are predicted to form the membrane spanning segment of the
calcium release channel. The majority of RYR1 mutations
giving rise to MH and CCD were found in regions 1 and 2;
recently however, 16 novel mutations predominantly associated
with CCD were found in exons 94–106 (23–25).
Although RYR1 was thought to be almost exclusively
expressed in skeletal muscle, several reports have demonstrated
that circulating human B-lymphocytes, Epstein–Barr Virus
(EBV)-immortalized lymphoblastoid cells and murine dendritic
cells express a functional type 1 RYR calcium release channel
(24,26–28). Thus, measurements of the intracellular Ca2þ
concentration, [Ca2þ]i in EBV-immortalized lymphoblastoid
cells from patients can be used to assay the function of RYR1
mutations ex vivo (24,26). In the present study we characterized
the functional properties of RYR1s carrying a deletion which
was identified in a patient with a severe form of CCD.
RESULTS
RYR1 mutation analysis
Upon mutation screening by SSCA an aberrant fragment was
noted in exon 101 of the patient’s DNA. Subsequent
sequencing disclosed a deletion of nucleotides 14588–14606
(TCTACAACAAGAGCGAGG) in the heterozygous state. The
deletion was also present in the DNA of the patient’s mildly
affected mother but absent in her healthy father. Figure 1 shows
an agarose gel of the PCR amplified DNA products: the
genomic DNA from the unaffected father exhibited a 176 bp
DNA fragment while amplification of the DNA from the
proband and her mother yielded two fragments of 176 bp (wild-
type) and 158 bp (deletion). The deletion results in the removal
of seven amino acids (4863–4869, FYNKSED) and insertion of
a novel tyrosine residue (RYR1 D4863–4869 deletion mutant),
thus leading to a net in-frame deletion of six amino acids.
Figure 2 shows that the deleted amino acids are present and
conserved in all known vertebrate RYR isoforms.
Functional studies of cells expressing the native
mutated RYR1 calcium channel
We used EBV-immortalized lymphoblastoid cells from the
proband and her mother to study the functional effect of
the newly identified RYR1 D4863–4869 deletion mutant. The
presence of the RYR1 gene mutation in the cell lines was
checked by PCR amplification using a set of primers spanning
exons 100–101. As shown in Figure 3A the cDNA prepared
from EBV-immortalized lymphoblastoid cells from the proband
showed two bands of 224 and 206 bp, while the cDNA
prepared from control lymphoblastoid cells showed one band
of 224 bp. The identity of the cDNA fragment was confirmed
by direct sequencing (not shown).
We proceeded to test the functional effect of the RYR1
deletion on intracellular calcium homeostasis. Lymphoblastoid
cells were loaded with the fluorescent calcium indicator fura-2/
AM and their [Ca2þ]i monitored in nominally Ca
2þ-free
EGTA-containing Krebs–Ringer buffer. Figure 3B shows that
cells harbouring the RYR1 deletion released calcium from
intracellular stores when placed in Krebs–Ringer medium
containing 0.5 mM EGTA. This increase in fluorescent ratio did
not occur in cells from control individuals (Fig. 3C). The
released calcium was contained within an intracellular store
endowed with a SERCA type Ca-ATPase since the addition of
400 nM thapsigargin failed to cause a further increase in the
[Ca2þ]i, whereas the addition of thapsigargin to cells from
control individuals caused an immediate transient increase in
the [Ca2þ]i (panel 3C). The ‘unprompted’ calcium release was
Figure 1. Identification of a RYR1 deletion in a patient affected by severe CCD
and in her mildly affected mother. Genomic DNA was amplified by PCR using
a set of primers spanning exon 101 of the RYR1 gene; DNA fragments were
separated on a 3% agarose gel. Amplification of the unaffected father’s DNA
yielded a single band of 176 bp, while amplification of the affected daughter’s
and mother’s DNA yielded two bands of 176 and 158 bp, respectively, indicat-
ing a deletion of 18 bp in one allele.
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seen in nine out of 14 experiments. However, in those experi-
ments in which no transient was observed, the thapsigargin-
sensitive intracellular stores were smaller than those observed
in cells from control individuals. The results depicted in
Figure 3D show that the presence of the RYR1 D4863–4869
deletion causes a significant depletion of calcium from the
thapsigargin sensitive stores (*P< 0.0001). In order to confirm
that the calcium release was due to a leaky RYR1 channel, we
carried out experiments in the presence of dantrolene, a specific
inhibitor of the skeletal muscle ryanodine receptor (29,30).
Pre-treatment of cells with 10 mM dantrolene blocked the
‘unprompted’ calcium release from the cells harbouring the
RYR1 D4863–4869 deletion (see insert traces in Fig. 3B) and
brought the thapsigargin-sensitive [Ca2þ]i stores of the cell
lines harbouring the RYR1 D4863–4869 deletion, to levels
indistinguishable from those of controls (Fig. 3D; P> 0.5).
Functional properties of cells transiently expressing the
recombinant RYR1 D4863–4869 deletion mutant
In order to directly study the biophysical properties of RYR1
carrying the homozygously expressed deletion, we constructed
the full-length rabbit RYR1 cDNA carrying a deletion of amino
acids 4863–4869 and transiently expressed it in HEK293 cells.
Under our experimental conditions, cells transfected with this
construct showed no noticeable activity, as determined by
[3H]ryanodine binding [0.15 0.05 and <0.02 pmol/mg
protein for wild-type (wt)-RYR1 and RYR1 D4863–4869,
respectively, n¼ 3]. The absence of binding was not due to lack
of expression of the deleted protein, as a major immunoreactive
band with an intensity comparable to wt-RYR1 was visible on
western blots (Fig. 4A). The presence of an ion conducting
activity in the RYR1 D4863–4869 deletion mutant was
determined in single-channel measurements with the planar
lipid bilayer method. Channels carrying the deletion were less
stable than the wild-type channels and disappeared rapidly
when recorded at membrane potentials greater than  20 mV.
As shown in Fig. 4B, a decrease in cis (cytosolic) Ca2þ
concentration from 2 mM to 130 nM nearly fully closed the wild-
type channel. In contrast, mutant channel activity was not
noticeably affected when the cis Ca2þ concentration was
lowered from 2 mM to 130 nM (Fig. 4B) or to 1 nM (not shown).
The mutant channels were not modified by ryanodine and their
Kþ conductance was lower than that of the wild-type
recombinant RYR1 (conductance of 576 pS, which is lower
than that of the wild-type recombinant RYR1 of 785 pS;
Fig. 4B and D). Wild-type and mutant channels were identified
by their ability to conduct Ca2þ (2.2 and 0.8 pA for wild-type
and mutant channels, respectively, at 0 mV with 10 mM Ca2þ as
current carrier; Fig. 4C) and their inhibition by ruthenium red
(Fig. 4C), a potent inhibitor of the RyRs (31).
Membrane topology of the domain encompassing RYR1
D4863–4869 deletion
In order to determine the topology of the portion of the RYR
encompassing the deleted amino acids, we cloned the rabbit
RYR1 cDNA sequences encompassing putative domain M8
(amino acids V4830 to D4870, corresponding to a peptide with
a calculated molecular mass of 4945 Da) and M10 (amino acids
Figure 2. Alignment of the COOH-terminal region encompassing the deleted amino acids in 19 vertebrate RYR genes. Identical amino acids are indicated by a
horizontal dash. The last line indicates the deletion found in the present patients.
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D4907 to L4943, corresponding to a peptide with a calculated
molecular mass of 4544 Da) (3) in-frame at the COOH-
terminus of the reporter protein GFP. Tsa201 and COS-7 cells
were transfected with the EGFP or the GFP-tagged constructs
and membrane fractions prepared. Figure 5A and B shows that
the GFP immunoreactivity remained within the integral
membrane fraction (P) when the GM8 and GM10 constructs
were examined, and no immunoreactivity was present in the
soluble fraction (S) after high salt and 100 mM Na2CO3
extraction. On the other hand, when cells were transfected with
the pEGFP plasmid, the immunoreactive band was in the
soluble, post-microsomal supernatant (Fig. 5C). The panels on
the right show the GFP fluorescence of COS-7 cells transfected
with the three constructs: a diffuse punctuated perinuclear
fluorescence, typical of intracellular membrane distribution
was obtained upon transfection with GM8 and GM10; this is
different from the fluorescence exhibited by cells transfected
with the pEGFP plasmid.
To demonstrate that polypeptides M8 and M10 span the
membrane when expressed as recombinant proteins in hetero-
logous cells, we also used a sandwich assay: the COOH-termini
of both constructs were tagged with a FLAG-tag while the GFP
tag was maintained at the NH2 termini (Fig. 6A). We would like
to point out that addition of three copies of the negatively
charged FLAG epitope causes the polypeptides to migrate more
slowly than expected in SDS–PAGE. Figure 6B shows a
western blot of the microsomal proteins (or of proteins present
in the post microsomal supernatant) of Tsa 201 cells
transfected with pEGFP (lane 1), pEGFP-FLAG (lane 2),
GM8FLAG (lane 3) and GM10FLAG (lane 4). The FLAG-
tagged constructs have a lower than expected mobility.
The microsomal fractions of Tsa201 cells transfected with
the GM8FLAG and GM10FLAG constructs were treated
with proteinase K. If the GFP immunoreactivity disappears
and that of the FLAG tag remains, then the protein must be
oriented with GFP facing the cytoplasm; if the immunoreac-
tivity with both antibodies disappears then the polypeptide does
not completely span the bilayer. When experiments were
performed with the GM8FLAG construct, the GFP tag was
Figure 3. EBV-immortalized lymphoblastoid cells from the patient harbouring
the RYR1 D4863–4869 deletion mutant release calcium in the absence of RYR
activators. (A) 7.5% polyacrylamide gel showing that PCR amplification of
cDNA from lymphoblastoid cells with primers spanning exons 100–101 of
the human RYR1 gene gives rise to a band of 224 bp (lane 1, DNA from control
cells) or a doublet of 224 and 206 bp (lane 2, DNA amplification from the pro-
band carrying the RYR1 D4863–4869 deletion mutant. (B and C) Cells were
loaded with the fluorescent calcium indicator fura-2/AM as described in the
Methods section. Prior to the [Ca2þ]i measurements, 0.75 106 cells/ml were
centrifuged, resuspended in nominally Ca2þ-free Krebs–Ringer and placed in
the fluorimeter cuvette. Lymphoblastoid cells from the proband carrying the
RYR1 D4863–4869 deletion mutant exhibit an increase in the [Ca2þ]i in the
absence of exogenous trigger agents. The addition of 400 nM thapsigargin
caused no further changes in the [Ca2þ]i (B). Lymphoblastoid cells from a con-
trol individual did not exhibit the ‘unprompted’ calcium release and the addi-
tion of 400 nM thapsigargin caused an increase in the [Ca2þ]i (C). Traces are
representative of experiments carried out at least four times on three different
days. The insert of (B) shows that addition of 10mM dantrolene to the Ca2þ-free
Krebs–Ringer in the cuvette blocked the unprompted [Ca2þ]i increase observed
in the lymphoblastoid cells carrying the deletion. Inserts of (B) and (C) show
a typical trace obtained when cells were pretreated with 10 mM dantrolene.
(D) Peak Ca2þ induced by the addition of 400 nM thapsigargin in cells from
the individuals carrying the RYR1 D4863–4869 deletion mutant or from con-
trols were pre-treated with or without 10mM dantrolene. Results are expressed
as mean peak calcium released (±SD of n experiments). *P< 0.0001 using the
Student’s t-test for paired samples.
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accessible to proteinase K (Fig. 6C); on the other hand the
FLAG tag was not accessible to proteinase K and an anti-
FLAG immunopositive band of approximately 18 kDa (asterisk
in Fig. 6C) was present in the protein extracts after digestion.
When the same experimental approach was applied to the
GM10FLAG construct, the results were different. In fact,
digestion with proteinase K did not eliminate immunoreactivity
of the GFP tag, although the immunoreactive band was smaller,
confirming proteolysis (Fig. 6D). On the other hand, immuno-
reactivity of the FLAG tag disappeared after digestion,
indicating it faces the cytoplasm.
DISCUSSION
In the present study we identified a patient of European origin
affected by CCD, carrying a heterozygous deletion of seven
amino acids (and insertion of a Tyr) in the COOH-terminal
domain of the RYR1 gene. Most known nucleotide substitu-
tions in the RYR1 associated with MH and CCD replace single
amino acids, the most common being the loss or gain of a
positively charged arginine residue. Recently Monnier et al.
(23) reported short (1–3 amino acid) deletions within the
COOH-terminal domain of the RYR of patients affected by
‘classical’ CCD.
In this study we extended previous results (24,26) by
showing that EBV-transformed lymphoblastoid cell lines
established from the two CCD patients display the following
features: (i) they have depleted thapsigargin-sensitive intracel-
lular calcium stores; (ii) they exhibit release of calcium from
intracellular stores in the absence of the addition of a
pharmacological activator of the RYR1; and (iii) the unelicited
calcium transient from the thapsigargin-sensitive stores could
be blocked by dantrolene, a specific inhibitor of the skeletal
muscle RYR (29,30). The ‘unprompted’ intracellular calcium
transient was observed in 64% (9/14) of the experiments. In the
remaining experiments we observed only the tail of the
declining phase of the calcium transient. In this cell population
as well, the size of the thapsigargin-sensitive stores was similar
to that of the cells exhibiting a complete transient. The most
likely explanation for the ‘tail’ of the transient, is that we did
not capture the complete event of the ‘unprompted’ calcium
transient but only its final part. The tail signal is reminiscent of
that observed in fura-2 loaded cytotoxic T lymphocytes (32).
Figure 4. Immunoblots and single channel recordings for wt-RYR1 and RYR1
D4863–4869. (A) Equal amounts of membranes (6 mg protein/lane) isolated
from HEK293 cells expressing wt-RyR1 (left) and RYR1 D4863–4869 (right)
were probed with a monoclonal antibody raised against RYR1 (mAb D110) as
described in Materials and Methods. The upper major bands represent the intact
565 kDa RYR1 peptides and the lower ones proteolysis products. (B) One
wt-RYR1 (left) and two RYR1 D4863–4869 (right) channel currents were
recorded at 20 mV in symmetric 250 mM KCl containing the indicated
free cis Ca2þ concentrations and are shown as downward inflections (dotted
line, open channel current levels) from a closed state (solid line). Electrical
signals were filtered at 2 kHz. Channel open probability (Po) of wt-RyR1
was 0.12 0.03 and 0.01 0.01 (n¼ 16), and of RYR1 D4863–4869 was
0.45 0.08 and 0.43 0.08 (n¼ 5) at 2mM and 0.13mM cis Ca2þ, respectively.
(C) One wt-RYR1 (left) and two RYR1 D4863–4869 (right) channels currents
were recorded at 0 mV with 2 mM cis and trans Ca2þ (top traces), after the con-
secutive addition of 10 mM trans Ca2þ (second traces), 1 mM cis ATP (third
traces) and 10mM cis and trans ruthenium red (bottom traces). Electrical signals
were filtered at 0.3 kHz. Single channel Ca2þ currents in traces 2 and 3 were
2.2 0.2 pA (n¼ 3) for wt-RyR1 and 0.8 0.1 pA (n¼ 3) for RYR1 D4863–
4869). (D) Current–voltage relationship of wt (filled circles) and mutant (empty
circles) channels in 250 mM symmetric KCl with Kþ as current carrier. Wild-
type and mutant channels averaged Kþ conductances were 785 10 pS
(n¼ 5) and 576 16 pS (n¼ 14), respectively.
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We still do not know what causes the ‘unprompted’ calcium
release in the EBV-immortalized lymphoblasts, but it appears to
be an intrinsic characteristic of those cells carrying RYR
mutations/deletions associated with CCD which affect the
COOH-terminal amino acid sequences involved in the forma-
tion of the membrane spanning segments of the calcium release
channel (24). In fact EBV-immortalized lymphoblasts from a
patient carrying the recently identified CCD-linked RYR1
mutation P3527S (which should be located in the hydrophilic
portion of the RYR, not adjacent to the pore forming region)
(33), (i) did not show such ‘unprompted’ calcium release and
(ii) had thapsigargin-sensitive intracellular calcium stores
which were indistinguishable from those of controls
(S. Treves, A. Ferreiro, N. Monnier and J. Lunardi, unpublished
observations).
Interestingly, although the calcium release characteristics of
the cell lines established from the daughter and her mother
were similar, i.e. they had depleted thapsigargin-sensitive
pools, there was a marked difference in the clinical severity
between these two members of the family. This implies that
in vivo other factors modulate the penetrance of the RYR
deletion. Each individual may activate different compensatory
mechanisms in muscle tissue and it seems that EBV-
immortalized lymphocytes probably lack the proteins involved
in these mechanisms. Alternatively, the phenotypic differences
between mother and daughter may be linked to the levels of
expression of RYR1 channels carrying the deletion in vivo, i.e.
there may be differences in the number of homotetramers and
heterotetramers carrying the RYR1 deletion. Clearly studies
aimed at identifying the subunit composition of the channels
in vivo are necessary to clarify this issue.
To determine the functional consequences of the deletion,
cDNAs containing either wild-type or mutant cDNAs were
transfected into HEK293 cells. The expressed proteins were
characterized by [3H]ryanodine binding and single channel
Figure 5. Fusion proteins encompassing amino acid residues V4830–4870 and
4907–4943 of the rabbit skeletal muscle RYR1 are integral membrane proteins.
(A and B) Microsomes from Tsa201 cells transfected with the RYR1 cDNA
constructs tagged with GFP were washed with high salt and 100 mM
Na2CO3. Soluble proteins and proteins loosely associated with the membranes
(S) were separated from integral membrane proteins (P) by differential centri-
fugation. (C) Tsa201 cells were transfected with pEGFP and proteins present
in the microsomal or post microsomal soluble fraction were loaded on the
PAG. Twenty micrograms of protein were loaded per lane, separated on a
10% SDS–PAGE, blotted onto nitrocellulose and probed with anti-GFP anti-
bodies. The panels on the right show the GFP-fluorescence exhibited by
COS-7 cells transfected with the plasmids (magnification 1000).
Figure 6. Membrane topology of fusion proteins GM8 and GM10.
(A) Schematic representation of constructs used to transfect Tsa201 cells. A
FLAG tag was added to the COOH-terminus of GM8 and GM10 as described
in the Materials and Methods section. (B) The post microsomal supernatant of
Tsa201 cells transfected with pEGFP and pEGFP-FLAG (lanes 1 and 2, respec-
tively) or the microsomal fraction of Tsa201 cells transfected with GM8FLAG
and GM10FLAG (lanes 3 and 4) were loaded on a 15% SDS–PAGE, blotted
onto nitrocellulose, and probed with anti-GFP antibodies (20mg protein/lane).
(C and D) The microsomal fraction of Tsa201 cells transfected with
GM8FLAG and GM10FLAG was treated with or without proteinase K;
10 mg protein were loaded per lane, separated on a 12.5% SDS–PAGE, blotted
onto nitrocellulose and probed with anti-GFP or anti-FLAG antibodies. The
asterisk indicates the immunoreactive band obtained after digestion of the
GM8FLAG construct with proteinase K, when probed with anti-FLAG Abs.
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measurements. Both methods indicated a loss of regulation by
Ca2þ and ryanodine, providing biochemical confirmation that
the deletion is the likely cause of CCD. The mutant channels
will require more detailed characterization, however we noted
that the homozygous channels show constitutive Kþ and Ca2þ
conductance, which may explain that the deletion in RYR1
influences the Ca2þ permeability. The mutant Kþ and Ca2þ
conductances were lower than in wild-type, suggesting that the
deleted amino acids lie close or may be a part of the pore-
forming region of RYR1.
A great deal of information has been gathered on the nature
and structure of the RYR domain involved in the formation of
the conduction pore (34–36). Site-directed mutagenesis
experiments and comparison of the sequence of the RYR with
that of a potassium channel from Streptomyces lividans, whose
crystal structure has been defined (37), have indicated that the
amino acid residues lining the pore are defined by residues
4886–4910. The pore-forming domain overlaps with a region
originally defined as M9 (3) and is adjacent to the region
carrying the deletion, an area which is highly conserved in all
vertebrate RYRs examined to date (cf. Fig. 2). The definition of
the membrane topology of the latter region and that of the pore-
forming domain is thus crucial to understand the exact role of
RYR in the pathophysiology of CCD. Since the membrane
topology of this area has not been fully elucidated, we designed
a set of experiments to identify membrane spanning segments
in this region of the RYR1. We provide experimental evidence
that, when expressed as recombinant polypeptides in hetero-
logous cells, domains M8 and M10 are indeed membrane
spanning segments. The NH2-terminus of M8 is cytoplasmic,
while the region encompassing the deletion and connecting M8
to M10 is lumenal. On the other hand, the NH2-terminus of
M10 is in the lumen of the endoplasmic reticulum (see Fig. 7).
The presence of the newly identified deletion causes a
change in the charge of the segment directly adjacent to the
pore: of the six deleted amino acids, two are positively (one
arginine and one lysine) and one is negatively (glutamate)
charged, resulting in an overall more negatively charged
polypeptide. Studies aimed at determining the function of
charged residues in segments adjacent to ion conducting pores
have demonstrated that such changes in charge can greatly
affect the conductance properties of the channel (37). In this
case a reduced Kþ and Ca2þ conductance was recorded for the
mutant channel.
In conclusion, in the present report we demonstrate that the
functional characteristics of native and recombinant RYR1
carrying a seven amino acid deletion associated with CCD, are
severely altered and that the deleted amino acids are part of a
polypeptide segment connecting transmembrane segments M8
and M10 of the RYR1 calcium channel.
MATERIALS AND METHODS
Patients’ clinical details
The patient of Mediterranean origin was born by Caesarean
section at term, after an uneventful pregnancy. At birth she
had a left leg fracture and bilateral dislocation of hips
that were treated conservatively (double nappies). Her motor
development was delayed and she sat and crawled at 18 months.
At 2 years she was reviewed at the Hammersmith Hospital and
rehabilitated in calipers that she could use to stand with, but she
could not walk unsupported. A muscle ultrasound showed a
marked increase in echogeneicity and a needle muscle biopsy
confirmed the diagnosis of CCD. Since then, the patient has
been seen at yearly intervals. Now, at the age of 15 years she is
able to walk unsupported in calipers but uses a wheel-chair for
longer distances. Over time, she has developed a marked
lumbar lordosis and a moderate thoracolumbar scoliosis which
has been managed with a thoracolumbar orthosis. Overall, her
mobility and strength have improved and she is attending
regular school with good success. She occasionally complains
of generalized muscle pain following prolonged walking.
Her mother was first seen at the Hammersmith Hospital at
age of 31. Although she was asymptomatic, she was found to
have some mild facial weakness, with inability to bury her
eyelashes. A muscle ultrasound performed at the same time
showed a marked increase in echogeneicity and a needle
muscle biopsy showed a classical picture of CCD. Currently
aged 43 she only complains of frequent muscle pain and
cramps following even moderate exercise.
Lymphoblastoid cell lines
Mononuclear cells were isolated from peripheral blood
leukocytes and transformed with EBV according to the protocol
of Neitzel (38). Cells were cultured as described (26).
Mutation screening
Exons 98–103 of the RYR1 gene were screened for mutations
by single-strand conformation analysis (SSCA) and direct
sequencing as previously described (24). The presence of the
RYR1 gene deletion in exon 101 was confirmed by PCR
Figure 7. Cartoon depicting the proposed membrane topology of the COOH-
terminal domain of RYR1. The functional calcium release channel is made
up of four subunits. The putative regions involved in MH/CCD mutations are
indicated as well as the location of the deletion studied in this paper. The dark
grey cylinders in the bilayer represent transmembrane polypeptides GM8 and
GM10 which were investigated in the present report.
Human Molecular Genetics, 2003, Vol. 12, No. 4 385
amplification of genomic DNA as previously described (24).
The presence of the deletion in the cDNA of EBV-immortalized
lymphoblastoid cells was also verified by PCR as previously
described (26). Briefly, poly(Aþ) RNA was purified using a
commercially available kit (Qiagen). mRNA was converted into
cDNA using a cDNA synthesis kit, following the instructions
provided by the manufacturer (Roche Applied Science).
Amplification conditions were: 5 min at 95C, followed by 40
cycles of 45 s annealing at 55C, 45 s extension at 72C, 30 s
denaturation at 92C and extension for 4 min at 72C. The
following forward and reverse primers spanning exons
100–101 were used to amplify the cDNA: 50-TTC TTC TTT
GCT GCC CAT CT and 50-CGT CAT CAT GTC ATC ACA
CTT C, respectively. The presence of the mutation was detected
by electrophoresis in a 7.5% acrylamide gel and confirmed by
sequencing.
Construction and expression of RYR1 deletion mutant
Deletion of nucleotides encoding amino acids 4862–4868
(corresponding to 4863–4869 of human RYR1) of rabbit RYR1
and insertion of three bases encoding tyrosine were performed
by pfu polymerase-based chain reaction, using mutagenic
oligonucleotides and the QuickChange site-directed mutagene-
sis kit (Stratagene, La Jolla, CA, USA) as described pre-
viously (34). Briefly, the COOH-terminal fragment (ClaI/XbaI,
14443/15276) of RYR1 cDNA was subcloned into the
pBluescript vector and served as a template for PCR. The
construct was confirmed by sequencing. The fragment with
the deletion was cloned back into the original position of
EcoRI/XbaI (11766/15276) fragment of RYR1. The full-length
RYR1 cDNA with the deletion was constructed by ligating the
three fragments (ClaI/XhoI, XhoI/EcoRI, EcoRI/XbaI with
deletion) into the expression vector pCMV5 (ClaI/XbaI). Wild-
type and mutant RYR1 cDNAs were transiently expressed in
HEK293 cells transfected with Fugene 6 (Roche Applied
Science), according to the manufacturer’s instructions. Cells
were maintained at 37C and 5% CO2 in high glucose
Dulbecco’s minimum essential medium containing 10% fetal
bovine serum and plated the day before transfection. For each
10 cm tissue culture dish, 3–6 mg cDNA were used. Cells were
harvested 42–48 h after transfection and crude membrane
fractions were prepared as described (34).
[3H]Ryanodine binding
Bmax values of [
3H]ryanodine binding were determined by
incubating crude membranes for 4 h at room temperature with a
saturating concentration of [3H]ryanodine (40 nM) in 20 mM
imidazole, pH 7.0, 0.6 M KCl, 0.15 M sucrose, 20 mM leupeptin,
200 mM Pefabloc, and 100 mM Ca2þ. Non-specific binding was
determined using 1000-fold excess of unlabelled ryanodine.
After 4 h, aliquots of the samples were diluted with 8.5 vol of
ice-cold water and placed on Whatman GF/B filters preincu-
bated with 2% polyethyleneimine in water. Filters were washed
with three 5 ml ice-cold 100 mM KCl, 1 mM KPipes, pH 7.0.
The radioactivity remaining on the filters was determined by
liquid scintillation counting to obtain bound [3H]ryanodine.
Single channel recordings
Single channel measurements were performed by fusing
crude microsomal fractions with Mueller–Rudin type
bilayers containing phosphatidylethanolamine, phosphatidyl-
serine, and phosphatidylcholine in the ratio 5:3:2 (25 mg total
phospholipid/ml n-decane) (39). The side of the bilayer to
which the membranes were added was defined as the cis
(cytoplasmic) side. The trans (SR lumenal) side of the bilayer
was defined as ground. Single channels were recorded in a
symmetric KCl buffer solution (0.25 M KCl, 20 mM KHEPES,
pH 7.4) containing the additions indicated in the text. Electrical
signals were filtered at 2 kHz, digitized at 10 kHz and analysed
using a commercially available software package (pClamp 8.2,
Axon Instruments, Burlingame, CA, USA). Po values in
multichannel recordings were calculated using the formula S
iPo,i/N, where N is the total number of channels, and Po,i is
channel open probability of the ith channel.
Construction and expression of putative RYR1
transmembrane segments M8–M10
The pEGFP-C1 plasmid (Clontech) was modified by introdu-
cing a tag similar to the ‘FLAG’ tag in the plasmid’s multiple
cloning site. To achieve this the oligodeoxynucleotide 50-CGG
GAT CCG GAA TTG CGA TCG GAC GAG CGA AAG ACT
ACA AAG ACC ATG ACG GTG ATT ATA AAG ATC ATG
ATA TCG ATT ACA AGG ATG ACG ATG ACA AGAC TAG
TTC TAG AGC was used as a PCR template and amplified
with the following forward and reverse primers: 50-CGC GGA
TCC GGA ATT and 50-GGG GGG GGC TCT AGA,
respectively. Amplification was performed as described above
for mutation screening, using an annealing temperature of
51C. The PCR amplified product was subcloned into the
BamHI and Xba I sites of pEGFP-C1. The cDNAs encoding
rabbit RYR1 putative transmembrane fragments M8 and M10
were amplified by PCR using the full-length RYR1 cDNA as
template. Amplification was performed as described above
using an annealing temperature of 54C with the following
forward and reverse primers: 50-TCT GTC GAC CAC AAT
GGG AAA and 50-CCT CAT GTC GGA TCC GTC CTC,
respectively and 60C with the following forwards and reverse
primers: 50-CCC AGC GGT CGA CGA ATA CG and 50-GCT
CCT GCT GGG ATC GCA GCT. The SalI/BamHI restriction
enzyme sequence was added to facilitate cloning and sequen-
cing of the constructs. After digestion with the restriction
enzymes SalI and BamHI, the PCR products were subcloned in
frame into the pEGFP-C1 plasmid and into the modified
pEGFP-C1 FLAG Tag plasmid. We thus obtained fusion
proteins GM8 and GM8FLAG which encompass RYR1
residues V4830 to D4870 and fusion proteins GM10 and
GM10FLAG which encompass RYR1 residues D4907 to
L4943, respectively. All constructs were verified by direct
sequencing. COS-7 cells were transfected using lipofectin and
GFP-fluorescence was monitored as previously described (40).
Tsa201 cells were grown at 37C, 5% CO2 in MEM (Gibco
BRL) supplemented with Earl’s salts, 10% fetal bovine serum
and antibiotics. Cells were plated in 10 cm tissue culture dishes
and transfected with 5–10 mg DNA per plate, using the CaPO4
technique. Cells were harvested and subcellular fractions
386 Human Molecular Genetics, 2003, Vol. 12, No. 4
prepared 48 h post transfection. Total microsomes were
prepared from Tsa201 cells transfected with the EGFP, GM8,
GM10, EGFP-FLAG, GM8FLAG and GM10FLAG cDNA
constructs as previously described (26). A high-salt wash with
0.6 M KCl was added to remove proteins loosely associated
with membranes. Integral membrane proteins were separated
from their soluble counterpart by extraction with Na2CO3 as
previously described (41). The pellets were resuspended in
0.25 M sucrose, 10 mM HEPES pH 7.4.
Proteinase K digestion
The microsomal pellets of Tsa201 cells transfected with the
GM8FLAG and GM10FLAG were treated with proteinase K
(Roche Applied Science) for 5 min at 27C at different
proteinase K/protein ratios (from 1/25 to 1/200) as previously
described (41). The reaction was stopped by the addition of a
cocktail of anti-protease inhibitors (Roche Applied Science)
plus 1 mM PMSF and Laemmli loading buffer. Samples
were placed at 95C for 5 min and proteins were subsequently
processed for SDS–PAGE. The intactness of the vesicles was
checked by performing the tryptic digestion in the presence or
absence of several detergents.
Electrophoresis and western blotting
Proteins were processed for SDS/PAGE, blotted onto nitrocel-
lulose and probed with monoclonal anti-RYR1 (34), mono-
clonal anti-GFP (Roche Applied Science) and anti-FLAG tag
(Sigma Chemicals, St Louis, MO, USA, Anti-Flag M2)
antibodies. Peroxidase-conjugated anti-mouse IgG was used
to detect the primary antibody followed by chemiluminescence.
Intracellular Ca2þ measurements
Changes in the intracellular calcium concentration of the
lymphoblastoid cells were monitored with the fluorescent
calcium indicator fura-2/AM (Sigma Chemicals, St Louis,
MO, USA) as described (24,26,42). Fura-2 loaded cells
(0.7 106/ml; final fura-2 concentration 5 mM) were resus-
pended in Ca2þ-free Krebs–Ringer medium containing
0.5 mM EGTA and placed in a cuvette thermostated at 37C.
Fluorescence changes (ratio 340/380 nm) were measured in an
LS-50S Perkin–Elmer spectrofluorimeter equipped with a
magnetic stirrer. All measurements were made in Ca2þ-free
Krebs–Ringer buffer containing 0.5 mM EGTA. Experiments
were performed at least four times on three different days.
Statistical analysis
For the two group comparisons, Student’s t-test was used; the
overall statistical significance level was set to 5%.
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